Portfolio

EUSA Pharma

Specialty pharmaceutical company focused on oncology and critical care


EUSA marketed products, with infrastructure and sales force in European markets, and modest operations and sales in the United States. EW was backing Bryan Morton, the former CEO of EUSA Pharma, in a transaction to acquire several key assets of his old company to serve as a platform for a buy-and-build strategy. The goal with the investment was to transform the company into a growing trans-Atlantic specialty pharmaceutical company through acquiring and in-licensing products and companies with European revenue to leverage the current European infrastructure, as well as acquiring and in-licensing EU and US rights to specialty products that are in late-stage clinical trials and could be launched to accelerate revenue growth. EUSA Pharma was acquired by Recordati in March 2022.

Transaction Summary

Related News

“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA Pharma.”

Bryan Morton

Chairman, EUSA Pharma

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.